CRISPR Therapeutics Faces Pressure from Insider Sales and Weak Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Should l Buy CRSP?
Source: Benzinga
CRISPR Therapeutics AG's stock fell 6.26% as it crossed below the 5-day SMA, reflecting investor concerns amid broader market declines.
The recent insider selling by CEO Samarth Kulkarni, who sold over 90,000 shares, has unsettled investors, contributing to a stock price drop of over 10%. Additionally, the company reported only $890,000 in revenue for Q3, significantly below the consensus estimate of $8.06 million, further eroding investor confidence. This combination of insider sales and disappointing revenue growth has led to a decline in CRISPR's momentum score, indicating poor price trends and volatility.
As CRISPR navigates these challenges, the market is closely watching how the company addresses its revenue growth and investor sentiment, particularly in light of its ambitious gene-editing projects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics' Financing Plan Triggers Stock Price Drop
- Financing Impact: CRISPR Therapeutics announced plans to sell $350 million in convertible notes to raise funds, resulting in a stock price drop of over 12%, reflecting market concerns about potential dilution of existing shareholders' stakes.
- Market Reaction: As of 3:21 p.m. ET Tuesday, CRISPR's stock price stood at $52.51 with a market cap of $5.6 billion, indicating a cautious investor sentiment towards the financing needs of biotech startups.
- Financial Condition: At the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but total liabilities were $343.4 million, including $149 million in current liabilities, highlighting a tight financial management situation.
- Future Outlook: Despite the financing news causing a short-term stock decline, analysts have set a price target of $81.21 for CRISPR, suggesting a continued optimistic view on its long-term potential, especially with ongoing advancements in gene therapy.
See More
CRISPR Therapeutics Issues Debt to Advance Drug Portfolio
- Debt Issuance Plan: CRISPR Therapeutics announced its intention to issue $350 million in convertible notes for 'general corporate purposes,' a move that may dilute existing shareholders' stakes and reflects the company's tight funding situation.
- Market Reaction: Following this announcement, CRISPR's stock price fell over 12% on Tuesday, indicating investor concerns about the company's future financial health, especially given its total liabilities of $343.4 million.
- Cash Flow Status: As of the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but burned through $345 million last year on drug development, highlighting the high-risk nature of its funding usage.
- Clinical Trial Progress: Despite facing short-term challenges, CRISPR is conducting five clinical trials, and its analysts' consensus price target of $81.21 suggests ongoing market confidence in its long-term potential, presenting an opportunity for investors to consider entry.
See More
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
CRISPR Therapeutics Plans $350 Million Private Debt Offering
- Funding Initiative: CRISPR Therapeutics announced plans to raise $350 million through a private offering of convertible senior notes to support its gene-editing biotechnology research and development efforts, demonstrating the company's commitment to advancing innovative projects.
- Debt Structure: The debt securities will rank as senior unsecured obligations and are scheduled to mature in 2031, reflecting the company's financing strategy under current market conditions and investor demand.
- Market Reaction: Following the announcement of the funding plan, CRISPR Therapeutics' stock traded over 6% lower in Tuesday's premarket, indicating investor concerns about the company's future financial health, which may impact its short-term stock performance.
- R&D Support: By pursuing this debt financing, CRISPR aims to provide funding for further development of its gene-editing technologies, and despite facing market volatility, the company remains committed to driving breakthroughs in the biotechnology sector.
See More
CRISPR Therapeutics Plans $350 Million Convertible Notes Offering
- Financing Size: CRISPR Therapeutics AG announced its intention to offer $350 million in convertible senior notes through a private placement, which is expected to provide funding for general corporate purposes, although the market reacted negatively with an 8.23% drop in pre-market trading to $53.94.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, which may attract more investors and enhance the likelihood of successful financing.
- Debt Structure: The notes will be senior unsecured obligations maturing on March 1, 2031, with interest payable semiannually on March 1 and September 1, ensuring investors receive stable returns over the investment period.
- Market Impact: Despite the company's plans to enhance financial flexibility through this offering, the significant drop in stock price may reflect market concerns regarding its future growth potential, prompting investors to monitor subsequent market reactions and strategic adjustments.
See More
TD Cowen Upgrades Rivian to Buy, Raises Price Target
- Rating Upgrade: TD Cowen upgraded Rivian's stock from 'Hold' to 'Buy', indicating strong confidence in the electric vehicle maker's future performance, which is likely to attract more investor interest.
- Price Target Increase: The firm raised its price target on Rivian shares from $17 to $20, reflecting optimistic expectations regarding the potential demand for its upcoming R2 vehicle platform, which could significantly expand market reach.
- Positive Market Reaction: Following the upgrade, Rivian's stock traded over 4% higher in Tuesday's premarket, indicating market recognition of the company's growth prospects, which may further drive stock price increases.
- New Model Strategy: The R2 vehicle platform is seen as a crucial component of Rivian's strategic expansion, and if successfully launched, it will help enhance its position in the highly competitive electric vehicle market.
See More
CRISPR Therapeutics' Financing Plan Triggers Stock Price Drop
- Financing Impact: CRISPR Therapeutics announced plans to sell $350 million in convertible notes to raise funds, resulting in a stock price drop of over 12%, reflecting market concerns about potential dilution of existing shareholders' stakes.
- Market Reaction: As of 3:21 p.m. ET Tuesday, CRISPR's stock price stood at $52.51 with a market cap of $5.6 billion, indicating a cautious investor sentiment towards the financing needs of biotech startups.
- Financial Condition: At the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but total liabilities were $343.4 million, including $149 million in current liabilities, highlighting a tight financial management situation.
- Future Outlook: Despite the financing news causing a short-term stock decline, analysts have set a price target of $81.21 for CRISPR, suggesting a continued optimistic view on its long-term potential, especially with ongoing advancements in gene therapy.
See More
CRISPR Therapeutics Issues Debt to Advance Drug Portfolio
- Debt Issuance Plan: CRISPR Therapeutics announced its intention to issue $350 million in convertible notes for 'general corporate purposes,' a move that may dilute existing shareholders' stakes and reflects the company's tight funding situation.
- Market Reaction: Following this announcement, CRISPR's stock price fell over 12% on Tuesday, indicating investor concerns about the company's future financial health, especially given its total liabilities of $343.4 million.
- Cash Flow Status: As of the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but burned through $345 million last year on drug development, highlighting the high-risk nature of its funding usage.
- Clinical Trial Progress: Despite facing short-term challenges, CRISPR is conducting five clinical trials, and its analysts' consensus price target of $81.21 suggests ongoing market confidence in its long-term potential, presenting an opportunity for investors to consider entry.
See More
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
CRISPR Therapeutics Plans $350 Million Private Debt Offering
- Funding Initiative: CRISPR Therapeutics announced plans to raise $350 million through a private offering of convertible senior notes to support its gene-editing biotechnology research and development efforts, demonstrating the company's commitment to advancing innovative projects.
- Debt Structure: The debt securities will rank as senior unsecured obligations and are scheduled to mature in 2031, reflecting the company's financing strategy under current market conditions and investor demand.
- Market Reaction: Following the announcement of the funding plan, CRISPR Therapeutics' stock traded over 6% lower in Tuesday's premarket, indicating investor concerns about the company's future financial health, which may impact its short-term stock performance.
- R&D Support: By pursuing this debt financing, CRISPR aims to provide funding for further development of its gene-editing technologies, and despite facing market volatility, the company remains committed to driving breakthroughs in the biotechnology sector.
See More
CRISPR Therapeutics Plans $350 Million Convertible Notes Offering
- Financing Size: CRISPR Therapeutics AG announced its intention to offer $350 million in convertible senior notes through a private placement, which is expected to provide funding for general corporate purposes, although the market reacted negatively with an 8.23% drop in pre-market trading to $53.94.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, which may attract more investors and enhance the likelihood of successful financing.
- Debt Structure: The notes will be senior unsecured obligations maturing on March 1, 2031, with interest payable semiannually on March 1 and September 1, ensuring investors receive stable returns over the investment period.
- Market Impact: Despite the company's plans to enhance financial flexibility through this offering, the significant drop in stock price may reflect market concerns regarding its future growth potential, prompting investors to monitor subsequent market reactions and strategic adjustments.
See More
TD Cowen Upgrades Rivian to Buy, Raises Price Target
- Rating Upgrade: TD Cowen upgraded Rivian's stock from 'Hold' to 'Buy', indicating strong confidence in the electric vehicle maker's future performance, which is likely to attract more investor interest.
- Price Target Increase: The firm raised its price target on Rivian shares from $17 to $20, reflecting optimistic expectations regarding the potential demand for its upcoming R2 vehicle platform, which could significantly expand market reach.
- Positive Market Reaction: Following the upgrade, Rivian's stock traded over 4% higher in Tuesday's premarket, indicating market recognition of the company's growth prospects, which may further drive stock price increases.
- New Model Strategy: The R2 vehicle platform is seen as a crucial component of Rivian's strategic expansion, and if successfully launched, it will help enhance its position in the highly competitive electric vehicle market.
See More
